The translational relevance of “cytokinology” in T1DM pathogenesis stems from a recent study that demonstrates that downstream targeting with Baricitinib of JAK1 and JAK2 signaling, which is used by several cytokines, ameliorates the course of T1DM in newly diagnosed patients [49]. This evidence concerns the gene JAK2 and type 1 diabetes mellitus.